Q2 2019 Photocure ASA Earnings Call Transcript
All right. Well, good morning and welcome to Photocure's 2019 Second Quarter Update. I'm Dan Schneider, CEO and President of Photocure. With me today is Erik Dahl, CFO. I'll take you through a number of slides before Erik wraps up with financials, and then we'll go to Q&A, if that's okay.
A reminder, the usual disclaimers are in effect for today's presentation.
I thought I'll start today's presentation a little bit around the strategy, the 4 steps to become a transformative, multiproduct, bladder cancer company: step 1 is accelerate, growing the Cysview/Hexvix line. I think we put, and you know, considerable investment and effort and are starting to see the acceleration. This expansion and acceleration is important to setting up the foundation of the future for Photocure.
Expand. Our recent indication late last summer/early fall launched into the surveillance market open up a tremendous opportunity for Photocure as the market quadruples in terms of size for us to address. New geographies, whether it be Canada, New
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
